(Q37776074)

23 August 2017

1 reference

title

The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission (English)

1 reference

23 August 2017

Review: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission (English)

1 reference

https://api.crossref.org/works/10.1177/1359786810372978

11 June 2024

1 reference

1

Pierre-Michel Llorca

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

full work available at URL

23 August 2017

http://jop.sagepub.com/cgi/content/abstract/24/2/21

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20663805

http://journals.sagepub.com/doi/pdf/10.1177/1359786810372978

11 June 2024

1 reference

https://api.crossref.org/works/10.1177/1359786810372978

Journal of Psychopharmacology

11 June 2024

published in

1 reference

23 August 2017

volume

24

1 reference

23 August 2017

issue

2 Suppl

1 reference

23 August 2017

page(s)

21-26

1 reference

Discontinuation of use and switching of antidepressants: influence of patient-physician communication

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Treatment non-adherence in affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Diurnal mood variation in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Report by the ACNP Task Force on response and remission in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Pharmacotherapeutic treatment strategies for antidepressant nonresponse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1359786810372978

Six-month compliance with antidepressant medication in the treatment of major depressive disorder

21 January 2018

series ordinal

2

1 reference

https://api.crossref.org/works/10.1177/1359786810372978

Cognitive behavioral treatment of residual symptoms in primary major depressive disorder

11 June 2024

series ordinal

3

1 reference

https://api.crossref.org/works/10.1177/1359786810372978

The concept of recovery in major depression

11 June 2024

series ordinal

4

1 reference

https://api.crossref.org/works/10.1177/1359786810372978

11 June 2024

Identifiers

1 reference

23 August 2017

1 reference